FormBlends Publishes 2026 State of Peptides Report as RFK-Era HHS Signals Major Shifts for GLP-1 and Peptide Therapy Access in the United States
FormBlends released its 2026 State of Peptides and GLP-1 Regulation report, detailing changes in peptide therapy access in the US under the Robert F. Kennedy Jr. Department of Health and Human Services. The report maps the impact of new obesity drugs and FDA regulations on weight management and metabolic health.
FormBlends, a telehealth platform, has released its 2026 State of Peptides and GLP-1 Regulation report. The report examines the impact of the Robert F. Kennedy Jr. Department of Health and Human Services and new obesity drugs from Eli Lilly, Novo Nordisk, Boehringer Ingelheim, and Roche on peptide therapy access in the US. Robert F. Kennedy Jr. was confirmed as HHS Secretary in February 2025, resetting federal health priorities. The FDA's 503A list changes have affected bulk compounding, with some compounds moved to Category 2, ending legal bulk compounding. The 2026 budget request includes language about 'evidence review for therapeutic peptides,' suggesting potential re-evaluation of Category 2 designations.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.